Analysts Issue Forecasts for Septerna FY2026 Earnings

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Septerna in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($2.14) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 target price on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share.

Separately, Wells Fargo & Company boosted their price target on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a report on Friday, May 16th.

Septerna Stock Performance

SEPN traded up $0.14 during midday trading on Wednesday, reaching $10.42. 255,756 shares of the company's stock were exchanged, compared to its average volume of 832,849. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The business's 50-day moving average price is $7.77 and its 200 day moving average price is $12.58.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Rhumbline Advisers purchased a new position in Septerna in the fourth quarter valued at about $458,000. New York State Common Retirement Fund acquired a new stake in shares of Septerna in the fourth quarter valued at about $32,000. Bank of New York Mellon Corp purchased a new stake in shares of Septerna during the 4th quarter valued at about $872,000. Charles Schwab Investment Management Inc. acquired a new stake in Septerna in the fourth quarter valued at approximately $3,197,000. Finally, M&T Bank Corp acquired a new position in shares of Septerna during the fourth quarter worth $376,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.